Clinical Trial Update: A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS [Phase 2]

View source ↗

Summary

A Phase 2 double-blind study of Arimoclomol for amyotrophic lateral sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Arimoclomol (arimoclomol)

Snippet

Sponsor: CytRx | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: WITHDRAWN